What is Cagrilintide (CAGRI)?
Cagrilintide — supplied by Peptora under the research designation CAGRI — is a long-acting synthetic analog of amylin, a peptide hormone co-secreted with insulin by the beta cells of the pancreas. Natural amylin acts as a satiety signal, and Cagrilintide was engineered as a lipidated, stabilized version designed to remain active far longer than the native hormone. Because it engages amylin- and calcitonin-family receptors rather than the incretin receptors, it is described in the literature as an amylin analog rather than a GLP-1 or GIP agonist.
Cagrilintide has been investigated in metabolic research both on its own and, notably, in combination with the GLP-1 analog semaglutide — a pairing the scientific literature refers to as CagriSema. Throughout this guide the compound is referred to by its canonical research name, Cagrilintide (CAGRI). It is intended exclusively for laboratory research and is not a medicine.
The essentials at a glance
Amylin-analog agonist
A stabilized, long-acting analog of the pancreatic satiety hormone amylin.
The satiety angle
Amylin signaling has been studied in both homeostatic and hedonic brain regions tied to food intake.
Combination research
Frequently studied alongside semaglutide — the pairing referred to as CagriSema — for additive effects on appetite in research models.
99%+ verified purity
HPLC-verified and confirmed by LC-MS, with a batch-specific certificate of analysis.
Explore research-grade Cagrilintide
HPLC-verified to 99%+ purity, batch-specific COA, fast U.S. shipping — for laboratory research use only.
View Cagrilintide (CAGRI)How Cagrilintide works: the amylin pathway
Amylin is one of the body's natural satiety hormones. Released together with insulin after a meal, it has been studied for its role in signaling fullness through receptors expressed in the brainstem and hypothalamus. Cagrilintide was designed to reproduce and extend this signaling profile:
- Amylin / calcitonin-family receptors — the targets through which amylin's satiety signaling is characterized in research.
- Homeostatic pathways — brain regions studied for their role in baseline hunger and energy balance.
- Hedonic pathways — reward-related circuits studied in the context of food-intake and appetite research.
According to PubMed, the medicinal-chemistry work behind Cagrilintide addressed a specific challenge: native amylin is highly prone to forming amyloid fibrils, which makes it difficult to formulate. Researchers reported that lipidation and sequence modification produced a stable, long-acting analog suitable for once-weekly dosing schedules in clinical research.
Cagrilintide vs. incretin agonists
Cagrilintide is often discussed alongside the incretin-based research compounds, but it works through a distinct pathway. Rather than targeting the GLP-1, GIP, or glucagon receptors, it acts on the amylin system — which is why researchers study it as a complementary, rather than overlapping, mechanism. The table below places it in context:
| Compound | Primary pathway | GLP-1 | Class |
|---|---|---|---|
| Cagrilintide (CAGRI) | Amylin | — | Amylin analog |
| Semaglutide | Incretin | ✓ | Single (GLP-1) agonist |
| Tirzepatide (GLP-2 TRZ) | Incretin | ✓ | Dual (GLP-1/GIP) agonist |
| Retatrutide (GLP-3 RT) | Incretin | ✓ | Triple agonist |
Because the amylin and incretin pathways are separate but related, researchers have studied whether pairing them produces additive effects — the rationale behind the CagriSema combination. Peptora carries research-grade versions of several of these compounds, including Cagrilintide (CAGRI), GLP-3 RT (Retatrutide), and Tirzepatide (GLP-2 TRZ), each with its own batch-specific certificate of analysis.
What the research explores
In laboratory and clinical-research settings, Cagrilintide has been investigated across a handful of interconnected areas:
- Amylin signaling — how a long-acting amylin analog engages satiety pathways compared with native amylin and the shorter-acting analog pramlintide.
- Appetite regulation — food-intake and satiety endpoints associated with amylin-receptor activity in research models.
- Body-weight models — dose-response relationships evaluated in preclinical and early-phase clinical research.
- Combination research — the CagriSema pairing with semaglutide, studied for potential additive effects on appetite pathways.
Purity, testing, and certificates of analysis
In research, the reliability of a result depends on the identity and purity of the material behind it. Every batch of Cagrilintide from Peptora is HPLC-verified to 99%+ purity, confirmed by LC-MS identity testing, and screened across a full quality-control panel before release. Each order ships with a lot-specific certificate of analysis (COA) so the material can be matched to its documentation.
Amylin analogs are especially sensitive to aggregation, which makes verified identity and purity particularly important for reproducible work. To understand what each figure on a report means, see the guide on certificates of analysis.
Handling Cagrilintide in the laboratory
Cagrilintide is supplied as a lyophilized (freeze-dried) powder. Before research use it is reconstituted with bacteriostatic water, which is sold separately. Careful handling preserves peptide integrity and the validity of downstream work:
- 1Allow the sealed vial to reach room temperature before opening.
- 2Add bacteriostatic water slowly against the vial wall; swirl gently and do not shake.
- 3Let the powder dissolve fully before drawing.
- 4Store the reconstituted solution refrigerated and protected from light.
Full step-by-step protocols live in the reconstitution guide. Following them consistently is one of the simplest ways to keep research reproducible.
Scientific references
Cagrilintide (AM833) has been investigated in Novo Nordisk-sponsored clinical trials, including phase 2 dose-finding studies and the phase 3 CagriSema (REDEFINE) programme. The literature below is provided for educational context, per PubMed and ClinicalTrials.gov, and describes clinical and preclinical research on the compound — not the laboratory research product supplied by Peptora.
- 1Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a phase 2 trial. Lancet. 2021;398(10317):2160-2172. doi:10.1016/S0140-6736(21)01751-7 (ClinicalTrials.gov: NCT03856047).
- 2Kruse T, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021;64(15):11183-11194. doi:10.1021/acs.jmedchem.1c00565.
- 3Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025;393(7):635-647. doi:10.1056/NEJMoa2502081 (NCT05567796).
- 4D'Ascanio AM, et al. Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. Cardiol Rev. 2024;32(1):83-90. doi:10.1097/CRD.0000000000000513.
- 5Panou T, et al. Amylin analogs for the treatment of obesity without diabetes: present and future. Expert Rev Clin Pharmacol. 2024;17(11):1005-1013. doi:10.1080/17512433.2024.2409403.
- 6Eržen S, et al. Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity. Int J Mol Sci. 2024;25(3):1517. doi:10.3390/ijms25031517.
Explore research-grade Cagrilintide (CAGRI)
HPLC-verified to 99%+ purity, batch-specific COA, fast U.S. shipping — for laboratory research use only.
View Cagrilintide (CAGRI)Key takeaways
- Cagrilintide is Peptora's research designation CAGRI for a long-acting synthetic analog of the pancreatic satiety hormone amylin.
- It acts through the amylin/calcitonin-family receptor system — a pathway distinct from the GLP-1, GIP, and glucagon incretin receptors.
- It is studied both alone and in combination with semaglutide, a pairing the literature refers to as CagriSema.
- Published research on Cagrilintide is reported for educational context only and is not therapeutic or dosing guidance; the product is for laboratory research use only.
- Peptora's Cagrilintide is HPLC-verified to 99%+ purity with a lot-specific certificate of analysis in every order.
Frequently asked questions
This article is intended solely as an educational summary of publicly available scientific literature. Products offered by Peptora are supplied exclusively for laboratory research purposes and are not approved for human or veterinary use. The information presented should not be interpreted as medical advice, treatment recommendations, or clinical guidance.
